
The drugmaker reported higher quarterly profit and revenue, while analysts flagged the need to sustain domestic growth in coming quarters.
Mankind Pharma’s September-quarter profit rose 37.7% year over year to ₹716 crore, as revenue from operations increased to ₹4,338 crore from ₹3,697 crore a year earlier.
The company’s India business grew 14.8% to ₹3,657 crore, Business Standard reported. EBITDA rose 27.2% to ₹1,175 crore, and the margin improved to 27.1% from 25.0%.
Mankind shares rose in Tuesday trading. Business Standard reported an intraday gain of 6.5% on the BSE, extending Monday’s advance. As of 07:38 UTC Tuesday, the shares traded at ₹2,512.80, up 8.69% since the previous close.
Management retained its FY27 EBITDA margin guidance of 25.5% to 26.5% and forecast research and development spending at 2.8% to 3.0% of revenue, Business Standard reported.
JM Financial analysts said the quarter was seasonally favourable for companies with a large acute-drug business, and said sustained domestic performance in coming quarters remained important to watch. Systematix analysts cited improving domestic volumes, a higher chronic-drug contribution and export momentum as expected growth supports.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.